Dr. Ahsan Kamal, MD, PA

Dr. Kamal practices at HCA Florida Fawcett Hospital in Port Charlotte, Florida, part of HCA Healthcare.

Dr. Kamal's NPI, 1760602049, was assigned on April 27, 2007. Dr. Kamal graduated from Rawalpindi Medical College in 1985. Dr. Kamal holds Florida license ME97373.

Dr. Kamal's primary practice is HCA Florida Fawcett Hospital, at 21298 Olean Blvd, Port Charlotte, FL 33952 in Charlotte County. The practice phone is (941) 629-1181.

Dr. Kamal's primary practice is HCA Florida Fawcett Hospital in Port Charlotte, Florida, part of HCA Healthcare. Dr. Kamal is also affiliated with HCA Florida Englewood Hospital. Dmand AI also links Dr. Kamal to 1 more hospital, 1 group practice or clinic, 1 home health agency and 1 medical group, each named with a free account. Dr. Kamal's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamal practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Kamal's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Kamal is licensed in Florida.

Dmand AI lists acute diabetes, acute respiratory failure, acute stomach ulcer, anemia, bile duct problems, cardiac arrhythmia, cellulitis and chest pain among the conditions Dr. Kamal treats.

CMS data shows 2,995 Medicare services from Dr. Kamal across 7 procedure codes in 2024, for 546 Medicare patients. Medicare paid $244,744 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 546 Medicare patients who saw Dr. Kamal in 2024. The largest group is 75 to 84, with 222 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kamal's median patient age at 77, with 53% women.

In 2024, Dr. Kamal wrote 785 Medicare Part D claims for 328 patients. 91% of them were for generic drugs. CMS names the drug for 493 of them, across 20 drugs with 11 or more claims each, at $24,424 in total drug cost. In 2023, CMS named 599 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Kamal for performance year 2024, reported individually. Dr. Kamal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Kamal, published from 2015 to 2024. 2016 was the busiest year, with 2. The most frequent topics are Genetic Predisposition to Disease, Genome-Wide Association Study and Genotype. Dr. Kamal's most frequent co-authors are Michael J. Baine, MD, David Qian, MD, PhD and Walid I. Saliba, MD.

CMS Open Payments shows 3 general payments to Dr. Kamal from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $93.

Dr. Kamal graduated from Rawalpindi Medical College in 1985.

Dr. Kamal is in network with 3 carriers, including Excellus BlueCross BlueShield, Cigna and CMS Medicare. Medicare plans come from the most carriers, 2. Check the plan with the practice before a visit.